Therapeutic Effect of Montelukast for Treatment of Uremic Pruritus in Hemodialysis Patients.
BACKGROUND
Uremic pruritus is one of the most common disabling symptoms in patients with end-stage renal disease. We aimed to study the effect of montelukast sodium for the treatment of uremic pruritus lasting more than 3 months in patients undergoing hemodialysis and compare it with placebo.


METHODS
Eighty patients undergoing hemodialysis at 3 centers in Shiraz, Iran, were recruited to a randomized double-blinded controlled trial to receive 10 mg of montelukast or placebo, daily for 30 days. To assess the severity of pruritus, a visual analogue scale and the Detailed Pruritus Score, based on a combined score of severity and distribution of pruritus and sleep disturbance, were used. Sleep disturbance, severity, and distribution scores were added up to calculate the patients' final score at the start and the end of the study.


RESULTS
The mean reduction of visual analogue scale score was significantly greater in the montelukast group (2.73 ± 2.03) compared to that in the placebo group (5.47 ± 2.37, P < .001). Mean reduction in Detailed Pruritus Score was also greater in the montelukast group (3.24 ± 2.2 versus 6.44 ± 3.25, respectively, P < .001). The mean high-sensitivity C-reactive protein in the montelukast group decreased from 5.48 ± 3.86 µg/mL to 3.86 ± 3.58 µg/mL, while it increased in the placebo group from 6.69 ± 4.49 µg/mL to 8.14 ± 5.20 µg/mL.


CONCLUSIONS
Montelukast can be an add-on therapy in uremic pruritus, especially when pruritus is refractive to other treatments.
Mehdi
M
Mahmudpour
Jamshid
J
Roozbeh
Ghanbar Ali
GA
Raiss Jalali
Maryam
M
Pakfetrat
Shahrokh
S
Ezzat Zadegan
Department of Nephrology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. saghebf@gmail.com.
Mohammad Mehdi
MM
Sagheb
D000085:Acetates / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D002097:C-Reactive Protein / Q000032:analysis; D003521:Cyclopropanes; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011537:Pruritus / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods; D013440:Sulfides; D016896:Treatment Outcome; D014511:Uremia / Q000175:diagnosis / Q000209:etiology
D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D002097:C-Reactive Protein; C093875:montelukast